Article
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Basic & clinical pharmacology & toxicology - 1 Jul 2017
Saydam Faruk, Değirmenci İrfan, Birdane Alparslan, Özdemir Mahmut, Ulus Taner, Özbayer Cansu, Çolak Ertuğrul, Ata Necmi, Güneş Hasan Veysi
Abstract excerpt
Clopidogrel inhibits platelet activation and aggregation by blocking the P2Y12 receptor. Dual antiplatelet therapy with clopidogrel and aspirin is recommended treatment by current guidelines for patients undergoing percutaneous interventions. Recurrent ischaemic cardiac events after this treatment showed lack of clopidogrel responsiveness. We aimed to investigate the most noticeable variants in the genes involved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
